Even as the government flatly denies that its decision to increase the Covishield dose interval to 12-16 weeks is not due to vaccine shortage and is instead based on real-world data, there is no such real-world data to support its decision while it is common knowledge that acute shortage of vaccines is leading to a … Continue reading I would be reluctant to change Covishield dose interval at a time when we still have intense transmission: Gagandeep Kang
Medicines & Healthcare products Regulatory Agency (MHRA)
Vaccine dilemma: To take or not to take Covaxin
Since COVID-19 vaccination is not compulsory, a person walking into a site that provides only Covaxin can choose not to get vaccinated. But is it ethical to offer one health-care worker the Covaxin whose efficacy is unknown and another health-care worker the Covishield whose efficacy is known even though both face the same risk of … Continue reading Vaccine dilemma: To take or not to take Covaxin
UK uses an untested strategy to rapidly but partially protect people at risk
With the virus running amok in the country and vaccines in short-supply, the U.K. is attempting an untested strategy of delaying the second dose of both AstraZeneca and Pfizer vaccine even in the absence of data from large trials. The intent is to rapidly but partially protect more individuals who are at risk.